News

GPB Scientific Announces Initial Availability of Advanced Cell Separation Platform; Name Change to Curate Biosciences

CARLSBAD, Calif., /PRNewswire/ — GPB Scientific, Inc. has launched its go-to-market activities for the transformational Curate® Cell Processing System to streamline the manufacture of cell therapies, making them economically and reliably available to the largest number of patients. The company’s advanced cell separation platform is in evaluations at select biopharmas, contract manufacturers, and academic centers ahead of the system‘s upcoming commercial introduction. Anticipating the commercial launch, the company is changing its name to “Curate Biosciences” to better communicate its benefits to the gene and cell therapy industry

Cell therapies, typically made from a patient’s own cells, are increasingly important in the fight against cancer and other critical diseases. Curate Biosciences provides a superior cell separation, wash, and concentration solution to deliver more biologically potent results for revolutionary cell therapy treatments. 

The company’s Curate® Cell Processing System is a robust, simple, and automated system that has the potential to enable up to a 50% reduction in the total cost of autologous cell therapy production and a like reduction in the days required to produce a CAR-T dose. The Curate System more than doubles the recovery of patient-derived white blood cells and CD3+ T cell subsets, with exceptional purity in a single-step, closed microfluidic system. 

“Users are now testing the Curate System via our Technology Access Program and observing firsthand its innovative and industry leading ability to produce more high-quality white blood cells for CAR-T oncology cures,” said Mike Grisham, Curate Bioscience’s Chief Executive Officer. “GPB in our prior company name stood for getting people better,’ and this remains our core mission, but the new name reflects our unique capacity to provide more high-quality cells to produce cures for once-intractable diseases.

For more information visit https://www.curatebio.com/

Recent News

06/29/2022

Bio-plastics startup wins Lighthouse Labs pitch contest

Charlottsville, VA (Virginia Business) – While pitching to the sharks, entrepreneur Alec Brewer told them, “I do have white powder in my pocket,” before quickly clarifying that it wasn’t an illicit substance: “It’s PHB! It’s PHB!” The co-founder and CEO of Charlottesville-based biodegradable plastics manufacturer Ourobio, Brewer explained that his company makes PHB, or polyhydroxybutyrate,

06/26/2022

USA FDA Grants Fast Track Designation to ReAlta Life Sciences’ Lead Compound RLS-0071

ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE). RLS-0071 is the Company’s lead dual

06/20/2022

Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence

New patent covers the use of the full genetic panel measuring all five genetic biomarkers CHARLOTTESVILLE, Va., — Adial Pharmaceuticals, Inc. (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,351,154 was issued on June 7, 2022, by